A carregar...
ACTR-73. A PHASE II STUDY OF TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED, UNRESECTABLE GLIOBLASTOMA
BACKGROUND: Patients with newly diagnosed, unresectable glioblastoma multiforme (GBM) will usually receive concurrent temozolomide (TMZ) and radiation therapy. Some patients will also receive bevacizumab (BEV) if clinically indicated. Tumor treating fields (TTFields) have also been shown to be safe...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692684/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.060 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|